Ezgi Oymak
Overview
Explore the profile of Ezgi Oymak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sutera P, Deek M, Deek R, Guler O, Hurmuz P, Reyhan M, et al.
Adv Radiat Oncol
. 2024 May;
9(7):101507.
PMID: 38799104
Purpose: Emerging data suggest that metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can detect occult metastatic disease,...
2.
Onal C, Bozca R, Oymak E, Guler O
Rep Pract Oncol Radiother
. 2023 Oct;
28(4):541-550.
PMID: 37795226
Background: The aim of the study was to perform dosimetric comparisons of helical (H) and TomoDirect (TD) plans for whole-breast irradiation (WBI) with simultaneous integrated boost (SIB) in early-stage breast...
3.
Onal C, Guler O, Torun N, Oymak E, Reyhan M
Eur J Nucl Med Mol Imaging
. 2023 Jul;
50(12):3755-3764.
PMID: 37402832
Purpose: We examined the prognostic significance of early changes in primary tumor SUV measured with Gallium-68-labeled prostate-specific membrane antigen positron emission tomography ([Ga]Ga-PSMA-11-PET/CT) and serum PSA values after neoadjuvant androgen...
4.
Guler O, Oymak E, Yazici G, Ozkaya Akagunduz O, Cetinayak O, Erpolat P, et al.
Oncol Res
. 2023 Jun;
31(3):299-306.
PMID: 37305394
The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175...
5.
Onal C, Erbay G, Guler O, Yavas C, Oymak E
Prostate
. 2023 May;
83(12):1158-1166.
PMID: 37173804
Background: To evaluate the treatment outcomes and toxicity of definitive radiotherapy (RT) for prostate cancer (PC) patients using the simultaneous integrated boost (SIB) technique, which delivered 78 Gy to the...
6.
Onal C, Erbay G, Oymak E, Guler O
Radiother Oncol
. 2023 Apr;
184:109677.
PMID: 37084886
Purpose: We assessed early changes in apparent diffusion coefficient (ADC) and serum prostate specific antigen (PSA) values after definitive radiotherapy (RT) without androgen deprivation treatment in low- and intermediate-risk prostate...
7.
Anacak Y, Kurtul N, Nasuhbeyoglu D, Oymak E, Onal H
Lancet Oncol
. 2023 Mar;
24(4):312-314.
PMID: 36913957
No abstract available.
8.
Yavas G, Guler O, Gultekin M, Oymak E, Sari S, Yildiz F, et al.
Int J Gynecol Cancer
. 2023 Jan;
33(5):719-726.
PMID: 36635049
Objective: To investigate the prognostic factors for survival and toxicities in elderly (≥65 years) patients with endometrial cancer who underwent post-operative radiotherapy. Additionally, to compare the treatment outcomes between the...
9.
Oymak E, Bozca R, Guler O, Onal C
Med Dosim
. 2022 Dec;
48(1):61-66.
PMID: 36572598
We aimed to evaluate contralateral breast doses calculated with a Treatment Planning System (TPS) and verified with metal oxide semiconductor field effect transistor (MOSFET) detectors in patients with early-stage breast...
10.
Onal C, Sezen D, Oymak E, Bolukbasi Y
Int J Radiat Oncol Biol Phys
. 2022 Dec;
115(1):253-254.
PMID: 36526389
No abstract available.